Ocrelizumab accepted for EMA review
Ocrelizumab accepted for EMA review
Roche has announced that the European Medicines Agency (EMA) has validated the company’s Marketing Authorisation Application (MAA) of ocrelizumab for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) in the European Union (EU)...Read more - http://www.ms-uk.org/MSnews
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 11932 Views
-
Last post by NHE
-
- 0 Replies
- 1169 Views
-
Last post by NHE
-
- 0 Replies
- 1941 Views
-
Last post by frodo
-
- 0 Replies
- 1245 Views
-
Last post by frodo
-
- 0 Replies
- 2108 Views
-
Last post by NHE
-
- 0 Replies
- 1698 Views
-
Last post by frodo
-
- 0 Replies
- 1311 Views
-
Last post by NHE
-
- 1 Replies
- 1791 Views
-
Last post by frodo
-
- 0 Replies
- 2519 Views
-
Last post by NHE